These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

510 related articles for article (PubMed ID: 31465593)

  • 21. Safety of biologics in psoriasis.
    Kamata M; Tada Y
    J Dermatol; 2018 Mar; 45(3):279-286. PubMed ID: 29226369
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Emerging therapies in psoriasis: a systematic review.
    Lee EB; Amin M; Bhutani T; Wu JJ
    Cutis; 2018 Mar; 101(3S):5-9. PubMed ID: 29718027
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New and emerging therapies in psoriasis.
    Leonardi CL; Gordon KB
    Semin Cutan Med Surg; 2014 Mar; 33(2 Suppl 2):S37-41. PubMed ID: 24979544
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exposure-Response Modeling to Characterize the Relationship Between Ixekizumab Serum Drug Concentrations and Efficacy Responses at Week 12 in Patients With Moderate to Severe Plaque Psoriasis.
    Chigutsa E; Velez de Mendizabal N; Chua L; Heathman M; Friedrich S; Jackson K; Reich K
    J Clin Pharmacol; 2018 Nov; 58(11):1489-1500. PubMed ID: 29878382
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost per additional responder for ixekizumab and other FDA-approved biologics in moderate-to-severe plaque psoriasis.
    Al Sawah S; Foster SA; Burge R; Amato D; Schacht A; Zhu B; Hartz S; Leonardi C
    J Med Econ; 2017 Dec; 20(12):1224-1230. PubMed ID: 28760056
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Number needed to treat for interleukin inhibitors approved for the treatment of moderate-to-severe plaque psoriasis in Italy.
    Ravasio R; Costanzo A; Antonelli S; Maiorino A; Losi S
    Glob Reg Health Technol Assess; 2021; 8():53-57. PubMed ID: 36627878
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Response to IL-17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the IL-17A gene: results from a multicentre study of four European psoriasis cohorts.
    van Vugt LJ; van den Reek JMPA; Meulewaeter E; Hakobjan M; Heddes N; Traks T; Kingo K; Galluzzo M; Talamonti M; Lambert J; Coenen MJH; de Jong EMGJ
    J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):112-118. PubMed ID: 31287604
    [TBL] [Abstract][Full Text] [Related]  

  • 28. IL-17 inhibitors for psoriasis.
    Paek SY; Frieder J; Kivelevitch D; Menter MA
    Semin Cutan Med Surg; 2018 Sep; 37(3):148-157. PubMed ID: 30215631
    [TBL] [Abstract][Full Text] [Related]  

  • 29. No need to change the drug class: ixekizumab- following secukinumab-therapy in psoriasis.
    Bokor-Billmann T; Schäkel K
    J Dermatolog Treat; 2019 May; 30(3):216-220. PubMed ID: 30051725
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biologic therapies targeting the interleukin (IL)-23/IL-17 immune axis for the treatment of moderate-to-severe plaque psoriasis: a systematic review and meta-analysis.
    Erichsen CY; Jensen P; Kofoed K
    J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):30-38. PubMed ID: 31419343
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
    Reich K; Armstrong AW; Langley RG; Flavin S; Randazzo B; Li S; Hsu MC; Branigan P; Blauvelt A
    Lancet; 2019 Sep; 394(10201):831-839. PubMed ID: 31402114
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A review of emerging IL-17 inhibitors in the treatment of psoriasis focusing on preclinical through phase II studies.
    Campa M; Menter A
    Expert Opin Investig Drugs; 2016 Nov; 25(11):1337-1344. PubMed ID: 27687859
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: Results from a network meta-analysis.
    Warren RB; Gooderham M; Burge R; Zhu B; Amato D; Liu KH; Shrom D; Guo J; Brnabic A; Blauvelt A
    J Am Acad Dermatol; 2020 May; 82(5):1138-1149. PubMed ID: 31884091
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of emerging immunotherapies in psoriasis.
    Yiu ZZ; Warren RB
    Immunotherapy; 2015; 7(2):119-33. PubMed ID: 25713988
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER-3 study.
    Lebwohl MG; Gordon KB; Gallo G; Zhang L; Paul C
    J Eur Acad Dermatol Venereol; 2020 Feb; 34(2):301-309. PubMed ID: 31479549
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Successful intra-class switching among IL-17 antagonists: a multicentre, multinational, retrospective study.
    Gasslitter I; Kirsten N; Augustin M; Torz K; Mrowietz U; Eyerich K; Puig L; Hoetzenecker W; Schütz-Bergmayr M; Weger W; Wolf P; Reider N; Ratzinger G; Papageorgiou K; Meier TO; Maul JT; Anzengruber F; Navarini AA
    Arch Dermatol Res; 2019 Jul; 311(5):421-424. PubMed ID: 30879102
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Indirect comparison of anti-interleukin 17 targeted biological treatments for moderate-to-severe psoriasis.
    Díaz Acedo R; Galvan Banqueri M; Márquez Saavedra E
    J Clin Pharm Ther; 2020 Aug; 45(4):715-721. PubMed ID: 32386269
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Indirect comparisons of ixekizumab versus three interleukin-23 p19 inhibitors in patients with moderate-to-severe plaque psoriasis - efficacy findings up to week 12.
    Gottlieb AB; Saure D; Wilhelm S; Dossenbach M; Schuster C; Smith SD; Ramot Y; Thaçi D
    J Dermatolog Treat; 2022 Feb; 33(1):54-61. PubMed ID: 32299269
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Number Needed to Treat Network Meta-Analysis to Compare Biologic Drugs for Moderate-to-Severe Psoriasis.
    Leonardi CL; See K; Burge R; Sun Z; Zhang Y; Mallbris L; Garrelts A; Warren RB
    Adv Ther; 2022 May; 39(5):2256-2269. PubMed ID: 35316500
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systematic review of anti-drug antibodies of IL-17 inhibitors for psoriasis.
    Thomas LW; Lee EB; Wu JJ
    J Dermatolog Treat; 2019 Mar; 30(2):110-116. PubMed ID: 29737896
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.